AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06613308
Drug: Neoadjuvant immunotherapy combined with chemotherapy
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The treatment regimen consisted of a PD-1/PD-L1 monoclonal antibody in combination with a platinum-containing two-agent standard chemotherapy regimen administered every three weeks. Following two to four cycles of therapy, patients who demonstrated no evidence of disease progression were eligible for surgical resection, which was performed within three to four weeks after the conclusion of the last neoadjuvant therapy. Consolidation with a PD-1/PD-L1 monoclonal antibody was initiated within three to eight weeks after surgery and continued every three weeks. The efficacy of the treatment was evaluated according to the irRECIST criteria. Chemotherapy regimens were selected based on tumour histology and investigator judgement. In the event of poor tolerability, patients may switch between cisplatin or carboplatin treatments.
Trial: NCT06613308
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A platinum-containing two-agent standard chemotherapy regimen was administered every three weeks. Following a two-to-four-cycle therapy, if the patients were evaluated without progressive disease, patients undergo surgical resection within three to four weeks of the final neoadjuvant treatment. Postoperative adjuvant chemotherapy is then conducted in accordance with the recommended regimen outlined in the 2022 edition of the CSCO Guidelines for the Diagnosis and Treatment of Non-Small Cell Lung Cancer. The efficacy of the treatment was evaluated in accordance with the RECIST 1.1 criteria.~The chemotherapy regimens were selected based on the tumor histology and the judgement of the investigators, in accordance with the standard clinical practice. In the event of poor tolerability, patients may switch between cisplatin or carboplatin treatments.
Trial: NCT00073762
Drug: DVS-233 SR
RxNorm normalized name: rAAVrh74.MHCK7.DYSF.DV
DrugBank: S-23 (DB07419)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05496465
Drug: ARS-1
RxNorm normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single treatment of ARS-1.
Trial: NCT06045000
Drug: DC-806
RxNorm normalized name: DCS
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT04739592
Drug: alendronate sodium vitamin D3 tablets
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: once per week for one year
Trial: NCT06321120
Drug: variability-based lenvatinib regimen
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dosages and administration times were tailored within individual predefined ranges to accommodate personalized therapeutic regimens. As per protocol, the daily dose was limited to match or remain below the patients' pre-enrollment dosage level. In the initial 4 weeks of the follow-up, participants followed a fixed standard regimen with the app serving as a reminder, allowing for an adaptation period. Subsequently, the algorithm-driven treatment plan was implemented for an additional 10 weeks.
Trial: NCT05391880
Drug: BEBT-503 20mg
RxNorm normalized name: bebtelovimab
DrugBank: Bebtelovimab (DB16755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEBT-503 capsule
Trial: NCT05391880
Drug: BEBT-503 40mg
RxNorm normalized name: bebtelovimab
DrugBank: Bebtelovimab (DB16755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEBT-503 capsule
Trial: NCT05391880
Drug: BEBT-503 80mg
RxNorm normalized name: bebtelovimab
DrugBank: Bebtelovimab (DB16755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEBT-503 capsule
Trial: NCT05391880
Drug: BEBT-503 120mg
RxNorm normalized name: bebtelovimab
DrugBank: Bebtelovimab (DB16755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEBT-503 capsule
Trial: NCT05391880
Drug: BEBT-503 180mg
RxNorm normalized name: bebtelovimab
DrugBank: Bebtelovimab (DB16755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEBT-503 capsule
Trial: NCT05050305
Drug: Marizomib
RxNorm normalized name: Marizomib
DrugBank: Marizomib (DB11762)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Infusion
Trial: NCT05050305
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Taken orally
Trial: NCT05050305
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Taken orally
Trial: NCT06229041
Drug: Camrelizumab ＋Immunotherapy
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab was used in preoperative treatment.
Trial: NCT06451666
Drug: Pilocarpine HCl Ophthalmic Solution
RxNorm normalized name: pilocarpine hydrochloride Ophthalmic Solution
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pilocarpine HCl ophthalmic solution 1.25%, one drop in each eye, once daily, for up to 30 days
Trial: NCT06494501
Drug: Inclisiran
RxNorm normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects will be administered a single subcutaneous injection of 284 mg inclisiran for injection at predefined time points.
Trial: NCT05221320
Drug: Ulixertinib
RxNorm normalized name: Ulixertinib
DrugBank: Ulixertinib (DB13930)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: small molecule ERK 1/2 inhibitor
Trial: NCT05221320
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Autophagy inhibitor
Trial: NCT05294965
Drug: Fenoterol
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT06199427
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib 7 mg/m2 from day +5 after HSCT
Trial: NCT05743777
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 400 mg IV q6 weekly for a maximum of 18 cycles
Trial: NCT05743777
Drug: MET-4
RxNorm normalized name: Met
DrugBank: Methionine (DB00134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cycle 1: 5 g (10 capsules) on days -7 and -6 and 1.5 g (3 capsules) on day -5 and every day thereafter Cycle 2 onwards: 1.5 g (3 capsules) daily
Trial: NCT04728698
Drug: COVI-MSC
RxNorm normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells (MSCs)
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 10\^6 MSCs/kg or 1.5 x 10\^6 MSCs/kg, depending on CRP level
Trial: NCT05174156
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1210 (camrelizumab) + albumin-bound paclitaxel + Carboplatin
Trial: NCT05258682
Drug: Bromelains
RxNorm normalized name: Bromelains
DrugBank: Bromelains (DB13281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromelain combined with Acetylcysteine (BromAc), administered simultaneously.
Trial: NCT05258682
Drug: Acetylcysteine
RxNorm normalized name: Acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bromelain combined with Acetylcysteine (BromAc), administered simultaneously.
Trial: NCT05753735
Drug: Piperacillin/Tazobactam
RxNorm normalized name: PIPERACILLIN/TAZOBACTAM
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piperacillin/Tazobactam 3.375 g IV every 6 hours while inpatient following surgery, not to exceed 10 days
Trial: NCT05753735
Drug: Amoxicillin/ Clavulanic acid
DrugBank: Clavulanic acid (DB00766)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin/ Clavulanic acid 875/125 mg every 12 hours after discharge to complete 10 days total antibiotics
Trial: NCT02279615
Drug: Mirabegron
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg of mirabegron per day will be given.
Trial: NCT02279615
Drug: Tamsulosin
RxNorm normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.4mg of flomax per day.
Trial: NCT04949282
Drug: Lutetium [177Lu] oxodotreotide/dotatate
DrugBank: Dotatate (DB14554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)
Trial: NCT04847583
Drug: Telacebec
RxNorm normalized name: Telacebec
DrugBank: Telacebec (DB17754)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telacebec 100 mg tablet
Trial: NCT06500429
Drug: NG101
RxNorm normalized name: Nirogacestat
DrugBank: Nirogacestat (DB12005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Including placebo
Trial: NCT06500429
Drug: Semaglutide Injectable Product
RxNorm normalized name: semaglutide Injectable Product
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Semaglutide 0.5 or 1 mg
Trial: NCT00001013
Drug: Trimetrexate glucuronate
RxNorm normalized name: Trimetrexate Glucuronate
DrugBank: Trimetrexate (DB01157)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001013
Drug: Pentamidine isethionate
RxNorm normalized name: Pentamidine Isethionate
DrugBank: Pentamidine (DB00738)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001013
Drug: Sulfamethoxazole-Trimethoprim
RxNorm normalized name: sulfamethoxazole-trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05978219
Drug: Mirtazapine Tablets
RxNorm normalized name: Mirtazapine Tablets
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirtazapine tablet form, orally, once or twice daily, 15-45 mg
Trial: NCT04835064
Drug: Nab paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Albumin combined with paclitaxel 125mg/m2 intravenous infusion, Day 1, 8, 15
Trial: NCT04835064
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion of 1000 mg/m2 was given for more than 30min on days 1, 8, and 15, and repeated every 4 weeks
Trial: NCT01280071
Drug: aminophylline
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06357520
Drug: Baxdrostat
RxNorm normalized name: Baxdrostat
DrugBank: Baxdrostat (DB19090)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baxdrostat tablet will be administered orally.
Trial: NCT06357520
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole capsule will be administered orally.
Trial: NCT05094414
Drug: Valacyclovir
RxNorm normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral valacyclovir 500 mg twice per day for 4 weeks
Trial: NCT06480136
Drug: SHR-A1921 injection and adebrelimab injection
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Treatment group receive SHR-A1921 injection combined with adebrelimab injection
Trial: NCT05924841
Drug: BL-B01D1
RxNorm normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion
Trial: NCT05924841
Drug: SI-B003
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion
Trial: NCT06315322
Drug: Brivaracetam Film-coated tablet
RxNorm normalized name: brivaracetam
DrugBank: Brivaracetam (DB05541)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Drug: Brivaracetam Film-coated tablet Pharmaceutical form: Film-coated tablet Route of administration: Oral use Brivaracetam film-coated tablet \[10, 25 or 50 mg\] will be administered twice per day in equal doses.
Trial: NCT06315322
Drug: Brivaracetam oral solution
RxNorm normalized name: brivaracetam Oral Solution
DrugBank: Brivaracetam (DB05541)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form: Oral solution Route of administration: Oral use Brivaracetam oral solution \[10 mg/mL\]) will be administered twice per day in equal doses.
Trial: NCT00002034
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002034
Drug: Ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05866471
Drug: Psilocybin
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The psilocybin is produced under Good Manufacturing Practice and is in a capsule that contains 25 mg of botanically-derived psilocybin.
Trial: NCT05362149
Drug: Darolutamide (Nubeqa, BAY1841788)
RxNorm normalized name: darolutamide
DrugBank: Darolutamide (DB12941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Retrospective cohort analysis, using PPS EMR prostate cancer database in the US.
Trial: NCT05362149
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Retrospective cohort analysis, using PPS EMR prostate cancer database in the US.
Trial: NCT05362149
Drug: Apalutamide
RxNorm normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Retrospective cohort analysis, using PPS EMR prostate cancer database in the US.
Trial: NCT05075863
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole as 5mg from day 3 to 7 of menstrual cycle
Trial: NCT04062721
Drug: In situ immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogel combining TLR or NOD2 agonist and GM-CSF will be injected in 1, 2 or 3 distinct lesions after RFA.
Trial: NCT06721442
Drug: Dapagliflozin (DAPA)
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients randomized to receive a daily dose of 10 milligrams of dapagliflozin were evaluated to assess the medication's impact on electrocardiographic parameters of repolarization, with focus on its potential to reduce ventricular repolarization prolongation in individuals with type 2 diabetes.
Trial: NCT06039137
Drug: Cetirizine
RxNorm normalized name: Cetirizine
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects were treated with a paclitaxel premedication regimen which contained oral cetirizine instead of intravenous clemastine
Trial: NCT06039137
Drug: Clemastine IV
DrugBank: Clemastine (DB00283)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects were treated with paclitaxel premedication containing clemastine 2 mg IV
Trial: NCT04708067
Drug: Bintrafusp Alfa
RxNorm normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05279131
Drug: Tirbanibulin ointment 1%
DrugBank: Tirbanibulin (DB06137)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Applied topically for 5 days over a field of approximately 100 cm\^2 on the face or balding scalp with AK.
Trial: NCT05223816
Drug: VG161
RxNorm normalized name: VG161
DrugBank: VG161 (DB18469)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Name: VG161 (Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) Concentration/Content: ≥1×107 PFU/mL; 1.0 mL/vial. Actual titer will be recorded on Certificate of Analysis.~Composition: VG161,50 mM Tris-HCl, 150mM NaCl, \<5% glycerol Route of Administration: Intratumoral injection or image guided intratumoral injections.
Trial: NCT05223816
Drug: Nivolumab Injection [Opdivo]
RxNorm normalized name: nivolumab Injection [Opdivo]
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: immunotherapy treatment
Trial: NCT05027919
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30mg subcutaneous injections of morphine 4 times daily on days 1 through 5.
Trial: NCT05027919
Drug: Naloxone + lofexidine pretreatment
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.4mg naloxone injection during the Naloxone challenge + pretreatment with oral lofexidine (25% of max daily dose scheduled during lofexidine taper)
Trial: NCT05027919
Drug: Naloxone + placebo pretreatment
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.4mg naloxone injection during the Naloxone challenge
Trial: NCT05027919
Drug: Lofexidine
RxNorm normalized name: LOFEXIDINE
DrugBank: Lofexidine (DB04948)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Lofexidine dosed per FDA label (4 times daily) on days 6 through 10.
Trial: NCT00256009
Drug: Cytotec
RxNorm normalized name: Cytotec
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05643729
Drug: Zofin
RxNorm normalized name: Zofin
DrugBank: Zofin (DB16519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Infusion (IV) of Zofin
Trial: NCT04794517
Drug: Dapagliflozin 10Mg Tab
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin 10 mg/die will be administered orally for six-weeks.
Trial: NCT06682234
Drug: obeldesivir
RxNorm normalized name: Obeldesivir
DrugBank: Obeldesivir (DB18821)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally
Trial: NCT05298683
Drug: Isatuximab
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous (IV) infusion. Dose regimen: Isatuximab will be given at a dose of 10 mg/kg QW by IV infusion on Days 1, 8, 15, and 22 in Cycle 1 and Days 1 and 15 in subsequent cycles. In patients with ≥VGPR who will be randomized to receive isatuximab once monthly from Cycle 7, isatuximab will be given on day 1 of each cycle.
Trial: NCT05298683
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Route of administration: Oral (PO). Dose regimen: Pomalidomide will be given at 4 mg orally (PO) will be given on Days 1-21 of each cycle.
Trial: NCT05298683
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Route of administration: PO or IV. Dose regimen: Dexamethasone will be given at 40 mg (20 mg for ≥75 years old) PO, or IV will be given on days 1, 8, 15, and 22 in each cycle.
Trial: NCT05298683
Drug: Ranitidine (or equivalent)
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Route of administration: IV. Dose regimen: Ranitidine or equivalent will be given at 50 mg 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion.
Trial: NCT05298683
Drug: Diphenhydramine (or equivalent)
RxNorm normalized name: diphenhydramine / hydrocortisone / pramoxine Medicated Pad or Tape
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Route of administration: IV. Dose regimen: Diphenhydramine or equivalent will be given at 25-50 mg 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion.
Trial: NCT06612580
Drug: 68Ga-AAZTA-NI-093
RxNorm normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-AAZTA-NI-093. Tracer doses of 68Ga-AAZTA-NI-093 will be used to image lesions of prostate cancer by PET/CT.
Trial: NCT05255601
Drug: Relatlimab
RxNorm normalized name: Relatlimab
DrugBank: Relatlimab (DB14851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified Dose on Specified Days
Trial: NCT05255601
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Specified Dose on Specified Days
Trial: NCT06236113
Drug: Ketamine 1 Mg/mL-NaCl 0.9% Intravenous Solution
RxNorm normalized name: ketamine 1 mg/mL-NaCl 0.9% intravenous solution
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administered at rate of 0.1 mg/kg/hr
Trial: NCT04536675
Drug: Vilanterol and Umeclidinium Bromide
RxNorm normalized name: vilanterol and umeclidinium bromide
DrugBank: Clidinium (DB00771)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative inhaler therapy with VI/UME (Vilanterol 25mcg/Umeclidinium 62.5mcg) once daily using Ellipta device from at least for 2 weeks preoperatively to at least 16 weeks post operatively.
Trial: NCT06007846
Drug: Namenda
RxNorm normalized name: Namenda
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Memantine 5 mg by mouth once daily, to be titrated up to 20 mg daily
Trial: NCT04282629
Drug: Milrinone Injection
RxNorm normalized name: milrinone Injection
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administration of milrinone (0.75 μg / kg / min, intravenous) from Day 4 to Day 14
Trial: NCT05183347
Drug: BI 1291583
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1291583
Trial: NCT05035745
Drug: Talazoparib
RxNorm normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with Talazoparib daily on a 4 weekly cycle (28 days)
Trial: NCT05035745
Drug: Selinexor
RxNorm normalized name: Selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will be treated with Selinexor once per week (3 out of 4 weeks), on a 4 weekly cycle (28 days)
Trial: NCT06104566
Drug: lisaftoclax +BTK inhibitor
RxNorm normalized name: BTK inhibitor CC-292
DrugBank: Lisaftoclax (DB18054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lisaftolax + BTK inhibitor